CYIO Quote, Financials, Valuation and Earnings

Astrana Health, Inc. has a net margin of -- compared to CYIOS Corp.'s net margin of 0.11%. CYIOS Corp.'s return on equity of -- beat Astrana Health, Inc.'s return on equity of 1.85%.

CYIOS Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Astrana Health, Inc. has an analysts' consensus of $37.6667 which suggests that it could grow by 57.8%. Given that Astrana Health, Inc. has higher upside potential than CYIOS Corp., analysts believe Astrana Health, Inc. is more attractive than CYIOS Corp..

CYIOS Corp. has a beta of 0.430, which suggesting that the stock is 57.015% less volatile than S&P 500. In comparison Astrana Health, Inc. has a beta of 0.862, suggesting its less volatile than the S&P 500 by 13.753%.

CYIOS Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CYIOS Corp. pays -- of its earnings as a dividend. Astrana Health, Inc. pays out -- of its earnings as a dividend.

CYIOS Corp. quarterly revenues are --, which are smaller than Astrana Health, Inc. quarterly revenues of $956M. CYIOS Corp.'s net income of -- is lower than Astrana Health, Inc.'s net income of $1.1M. Notably, CYIOS Corp.'s price-to-earnings ratio is -- while Astrana Health, Inc.'s PE ratio is 125.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CYIOS Corp. is 0.06x versus 0.40x for Astrana Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International, Inc. has a net margin of -- compared to CYIOS Corp.'s net margin of 9.58%. CYIOS Corp.'s return on equity of -- beat Cryo-Cell International, Inc.'s return on equity of --.

CYIOS Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Cryo-Cell International, Inc. has an analysts' consensus of $8.50 which suggests that it could grow by 129.73%. Given that Cryo-Cell International, Inc. has higher upside potential than CYIOS Corp., analysts believe Cryo-Cell International, Inc. is more attractive than CYIOS Corp..

CYIOS Corp. has a beta of 0.430, which suggesting that the stock is 57.015% less volatile than S&P 500. In comparison Cryo-Cell International, Inc. has a beta of 0.669, suggesting its less volatile than the S&P 500 by 33.089%.

CYIOS Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International, Inc. offers a yield of 17.57% to investors and pays a quarterly dividend of $0.15 per share. CYIOS Corp. pays -- of its earnings as a dividend. Cryo-Cell International, Inc. pays out 510.2% of its earnings as a dividend.

CYIOS Corp. quarterly revenues are --, which are smaller than Cryo-Cell International, Inc. quarterly revenues of $7.8M. CYIOS Corp.'s net income of -- is lower than Cryo-Cell International, Inc.'s net income of $749.4K. Notably, CYIOS Corp.'s price-to-earnings ratio is -- while Cryo-Cell International, Inc.'s PE ratio is 498.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CYIOS Corp. is 0.06x versus 0.95x for Cryo-Cell International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

P3 Health Partners, Inc. has a net margin of -- compared to CYIOS Corp.'s net margin of -20.12%. CYIOS Corp.'s return on equity of -- beat P3 Health Partners, Inc.'s return on equity of -223.63%.

CYIOS Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand P3 Health Partners, Inc. has an analysts' consensus of $10.25 which suggests that it could grow by 148.79%. Given that P3 Health Partners, Inc. has higher upside potential than CYIOS Corp., analysts believe P3 Health Partners, Inc. is more attractive than CYIOS Corp..

CYIOS Corp. has a beta of 0.430, which suggesting that the stock is 57.015% less volatile than S&P 500. In comparison P3 Health Partners, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

CYIOS Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. P3 Health Partners, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CYIOS Corp. pays -- of its earnings as a dividend. P3 Health Partners, Inc. pays out -- of its earnings as a dividend.

CYIOS Corp. quarterly revenues are --, which are smaller than P3 Health Partners, Inc. quarterly revenues of $345.3M. CYIOS Corp.'s net income of -- is lower than P3 Health Partners, Inc.'s net income of -$69.5M. Notably, CYIOS Corp.'s price-to-earnings ratio is -- while P3 Health Partners, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CYIOS Corp. is 0.06x versus 0.01x for P3 Health Partners, Inc.. Usually stocks with elevated PS ratios are considered overvalued.